| Old | New | Differences | |
|---|---|---|---|
| 1 | 1 | ||
| 2 | 2 | ||
| 3 | 3 | LCO No. 110 1 of 1 | |
| 4 | 4 | ||
| 5 | 5 | General Assembly Proposed Bill No. 436 | |
| 6 | 6 | January Session, 2025 | |
| 7 | 7 | LCO No. 110 | |
| 8 | 8 | ||
| 9 | 9 | ||
| 10 | 10 | Referred to Committee on GENERAL LAW | |
| 11 | 11 | ||
| 12 | 12 | ||
| 13 | 13 | Introduced by: | |
| 14 | 14 | SEN. ANWAR, 3rd Dist. | |
| 15 | 15 | ||
| 16 | 16 | ||
| 17 | 17 | ||
| 18 | 18 | AN ACT CONCERNING COST TRANSPARENCY IN LEGEND DRUG | |
| 19 | 19 | ADVERTISEMENTS. | |
| 20 | 20 | Be it enacted by the Senate and House of Representatives in General | |
| 21 | 21 | Assembly convened: | |
| 22 | 22 | ||
| 23 | 23 | That the general statutes be amended to require that each legend 1 | |
| 24 | 24 | drug advertisement, including, but not limited to, each direct-to-2 | |
| 25 | 25 | consumer legend drug advertisement and each legend drug 3 | |
| 26 | 26 | advertisement that is directed to health care providers, disclose the 4 | |
| 27 | 27 | portion of the legend drug cost that is attributable to the advertising 5 | |
| 28 | 28 | campaign. 6 | |
| 29 | 29 | Statement of Purpose: | |
| 30 | 30 | To promote transparency in legend drug costs, informed consumer | |
| 31 | 31 | decision-making and pharmaceutical manufacturer accountability. |